Elisabeth Bjork
CIK: 0001810406
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Sep 17, 2026PHVS
Pharvaris N.V.
Exercise(M)Direct17.5K shares at avg. $18.14$317K - Sep 17, 2026PHVS
Pharvaris N.V.
Sale(S)Direct52.5K shares at avg. $37.89$2.0M - Sep 17, 2026PHVS
Pharvaris N.V.
Exercise(M)Direct35K shares at avg. $14.39$504K - May 20, 2026PHVS
Pharvaris N.V.
Exercise(M)Direct10K shares at avg. $8.05$81K - May 20, 2026PHVS
Pharvaris N.V.
Sale(S)Direct10K shares at avg. $29.32$293K - Jan 2, 2026RCKT
ROCKET PHARMACEUTICALS, INC.
Purchase(P)Direct10K shares at avg. $3.44$34K - Aug 27, 2025RCKT
ROCKET PHARMACEUTICALS, INC.
Purchase(P)Direct10K shares at avg. $3.41$34K - Jun 18, 2025RCKT
ROCKET PHARMACEUTICALS, INC.
Award(A)Direct30K shares- - Sep 26, 2024RCKT
ROCKET PHARMACEUTICALS, INC.
Award(A)DirectStock Option (Right to Buy)
607 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 17, 2026 |  PHVS Pharvaris N.V. | Exercise(M) | 17,500 | $18.14 | $317,450 | Direct |
| Sep 17, 2026 | PHVS Pharvaris N.V. | Sale(S) | 52,500 | $37.89 | $1,989,409 | Direct |
| Sep 17, 2026 | PHVS Pharvaris N.V. | Exercise(M) | 35,000 | $14.39 | $503,650 | Direct |
| May 20, 2026 | PHVS Pharvaris N.V. | Exercise(M) | 10,000 | $8.05 | $80,500 | Direct |
| May 20, 2026 | PHVS Pharvaris N.V. | Sale(S) | 10,000 | $29.32 | $293,166 | Direct |
| Jan 2, 2026 |  RCKT ROCKET PHARMACEUTICALS, INC. | Purchase(P) | 10,000 | $3.44 | $34,400 | Direct |
| Aug 27, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | Purchase(P) | 10,000 | $3.41 | $34,100 | Direct |
| Jun 18, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | Award(A) | 30,000 | - | - | Direct |
| Sep 26, 2024 | RCKT ROCKET PHARMACEUTICALS, INC. | Award(A) Stock Option (Right to Buy) | 607 | - | - | Direct |
1-9 of 9 transactions
About Bjork Elisabeth
Bjork Elisabeth (SEC CIK 0001810406) files insider reports with the SEC as Director of Pharvaris N.V. (PHVS) and Director of ROCKET PHARMACEUTICALS, INC. (RCKT).
Signal8 holds 7 ownership filings by Bjork Elisabeth (1 Form 3, 6 Form 4), filed between Oct 29, 2024 and Sep 21, 2026. Those filings report 9 transactions, from Sep 26, 2024 to Sep 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bjork Elisabeth's filings is in LEXINGTON, MA.
Recent filings by Bjork Elisabeth
- Sep 17, 2026: Option exercise of PHVS shares (Form 4, code M).
- Sep 17, 2026: Open-market sale of PHVS shares (Form 4, code S).
- Sep 17, 2026: Option exercise of PHVS shares (Form 4, code M).
- May 20, 2026: Option exercise of PHVS shares (Form 4, code M).
- May 20, 2026: Open-market sale of PHVS shares (Form 4, code S).
Other insiders filing for Pharvaris N.V. (PHVS)
- Lu Peng, President
- Monges Viviane, Director
- Schikan Johannes Gerardus Christiaan Petrus, Director
- Nassif David W., CFO / CLO
- Glassman Robert, Director
- Lesage Anne, Chief Early Development